ESC Heart Failure

Article	Citations
Risk classification for long‐term mortality among patients with acute heart failure: China PEACE 4YMortality	76
Sex differences in the impact of frailty on patients with heart failure: A retrospective cohort study	68
Reductions in renin‐angiotensin system inhibitors following hospitalization for heart failure	63
Effect of beta‐blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta‐analysis	61
Fibroblast growth factor 23 independently predicts adverse outcomes after an acute coronary syndrome	58
Establishing a novel model to assess exercise capacity in chronic heart failure based on stress echocardiography	58
Calcium channel blockers and clinical outcomes in patients with continuous‐flow left ventricular assist devices	52
Prediction of cardiac events with non‐contrast magnetic resonance feature tracking in patients with ischaemic cardiomyopathy	51
Early achievement of walkability after cardiac surgery and the risk of cardiovascular disease after hospital discharge	49
Predicting cardiovascular events with fluoropyrimidine chemotherapy using a standard cardiovascular risk calculator	49
	49
Corrigendum	47
Characteristics and management of very elderly patients with heart failure: a retrospective, population cohort study	47
Left atrial unloading with an 8 mm septal cutting balloon to treat postcapillary pulmonary hypertension: a case report	46
Circ_0001206 regulates miR‐665/CRKL axis to alleviate hypoxia/reoxygenation‐induced cardiomyocyte injury in myocardial infarction	46
Synchronized diaphragmatic stimulation: a case report of a novel extra‐cardiac intervention for chronic heart failure	45
Clinical characteristics and frailty status in heart failure with preserved vs. reduced ejection fraction	44
Different activation of MAPKs and Akt/GSK3β after preload vs. afterload elevation	44
Systolic dysfunction and mortality in critically ill patients: more data are needed to believe in this association!	42
Burden of hospitalizations in newly diagnosed heart failure patients in Poland: real world population based study in years 2013–2019	40
Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan	39
Assessing the link of malnutrition with diabetes and mortality risk in heart failure patients	38
Models of cardiovascular surgery biobanking to facilitate translational research and precision medicine	38
Long‐term outcomes of electrical storm patients listed for urgent heart transplantation but not transplanted acutely	38
Cardiac involvement in patients recovering from Delta Variant of COVID‐19: a prospective multi‐parametric MRI study	37

Issue Information	37
Blood perfusion status is important in the prognosis of ventricular aneurysm complicated by ventricular septal rupture	37
Editors' highlight picks from 2023 in ESC heart failure	37
New insight: particle flow rate from the airways as an indicator of cardiac failure in the intensive care unit	36
Use of liver stiffness measurements in acute decompensated heart failure: new applications of a non‐invasive technique	36
Real‐time pulmonary artery pressure monitoring in heart failure patients: an updated cost‐effectiveness analysis	34
Integrated care for older multimorbid heart failure patients: protocol for the ESCAPE randomized trial and cohort study	34
Global differences in acute heart failure treatment: analysis of the STRONG‐HF site feasibility questionnaire	34
Uncovering the genetic links of SARS‐CoV‐2 infections on heart failure co‐morbidity by a systems biology approach	33
Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry	33
The use of MitraClip for nonobstructive hypertrophic cardiomyopathy with mixed severe mitral valve regurgitation	33
Predictive value of global longitudinal strain by left ventricular ejection fraction	33
Clinical course of patients with hypertrophic cardiomyopathy away from tertiary referral care	33
Impact of age on characteristics, performance measures and outcomes of inpatients for heart failure in Beijing, China	33
Serum angiotensin‐converting enzyme levels indicating early sarcoidosis diagnosis and immunosuppressive therapy efficacy	33
Oral milrinone for management of refractory right ventricular failure in patients with left ventricular assist devices	32
Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline‐induced takotsubo‐like syndrome	32
Sudden cardiac death after acute decompensation in heart failure patients: implications of discharge haemoglobin levels	32
Meta‐analysis of cardiac magnetic resonance in prognosticating left ventricular function in peripartum cardiomyopathy	32
Analysis of the serum levels of RIP3 and Drp1 in patients with heart failure	32
Machine learning‐based model for predicting 1 year mortality of hospitalized patients with heart failure	31
Explainable machine learning and online calculators to predict heart failure mortality in intensive care units	31
Acylation‐stimulating protein and heart failure progression in arrhythmogenic right ventricular cardiomyopathy	31
Atrial fibrillation ablation in patients with arrhythmia‐induced cardiomyopathy: a prospective multicentre study	31
Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines	30
Systemic immune‐inflammation index as a prognostic marker for advanced chronic heart failure with renal dysfunction	30
Right ventricular strain predicts outcome in patients receiving sacubitril/valsartan: A sub‐analysis of DISCOVER‐ARNI	30
Feasibility of patient‐performed lung ultrasound self‐exams (Patient‐PLUS) as a potential approach to telemedicine in heart failure	30
Oral iron supplementation in patients with heart failure: a systematic review and meta‐analysis	30
Heart failure and trimethylamine N‐oxide: time to transform a ‘gut feeling’ in a fact?	30
Prognostic value of hypoxaemic burden from overnight oximetry in heart failure with preserved ejection fraction	30
Prognostic value of left atrial strain in acute and chronic heart failure: A meta‐analysis	30
Health‐related quality of life among transthyretin amyloid cardiomyopathy patients	30
Discordance between estimated and measured changes in plasma volume among patients with acute heart failure	29
Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance	29
Meta‐Analysis Global Group in Chronic Heart Failure score for the prediction of mortality in valvular heart disease	29
Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIAST‐CHF study	29
Reaching consensus for unified medical language in Fontan care	28
Increased acylcarnitines in infant heart failure indicate fatty acid oxidation inhibition: towards therapeutic options?	28
Transcatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a systematic review and meta‐analysis	28
Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial	27
Prognosis and outcome determinants after heart failure diagnosis in patients who underwent aortic valvular intervention	27
Author reply: S‐ICD eligibilities in adults with congenital heart disease	27
Prognostic value of Growth differentiation factors 15 in Acute heart failure patients with preserved ejection fraction	27
Distinctive prognostic factor of heart failure with preserved ejection fraction stratified with admission blood pressure	27
Increased oxidative stress during exercise predicts poor prognosis in patients with acute decompensated heart failure	27
Soluble neprilysin and survival in critically ill patients	27
Circulating microRNA‐29‐5p can add to the discrimination between dilated cardiomyopathy and ischaemic heart disease	27
Serum creatinine and cystatin C‐based estimates of glomerular filtration rate are misleading in acute heart failure	27
Importance of non‐cardiovascular comorbidities in atrial fibrillation and heart failure with preserved ejection fraction	26

Digital health in older adults for the prevention and management of cardiovascular diseases and frailty. A clinical consensus statement from the ESC Council for Cardiology Practice/Taskforce on Ger	26
Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction	26
Delay in cardiology consultation after primary care physician referrals in heart failure: Clinical implications	26
Prognostic value of left atrial reverse remodelling in patients hospitalized with acute decompensated heart failure	26
Congestion, decongestion, renal function and diuretics in (ESC) heart failure	26
Correction to “Understanding the variability in red cell and plasma volume combinations can help guide management in heart failure”	26
Advances in device‐based treatment of heart failure with preserved ejection fraction: evidence from clinical trials	26
Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease	26
Increasing home‐time after a first diagnosis of heart failure in Sweden, 20 years trends	26
Prospective association of serum adipocyte fatty acid‐binding protein with heart failure hospitalization in diabetes	25
Study design and rationale of the pAtients pResenTing with cOngenital heaRt dIseAse Register (ARTORIA‐R)	25
Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: a meta‐analysis	25
Sex‐specific associations of cardiorespiratory fitness and galectin‐3 in the general population	25
Time‐domain heart rate variability features for automatic congestive heart failure prediction	25
Nutritional status during hospitalization is associated with the long‐term prognosis of patients with heart failure	25
Human epididymis protein 4 is a useful predictor of post‐operative prognosis in patients with severe aortic stenosis	25
Long‐term mortality in heart failure with mid‐range ejection fraction: systematic review and meta‐analysis	25
Role of skeletal muscle perfusion and insulin resistance in the effect of dietary sodium on heart function in overweight	25
Adrenomedullin peptides and precursor levels in relation to haemodynamics and prognosis after heart transplantation	24
Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery	24
Cost‐utility analysis of add‐on Qili Qiangxin capsules in chronic heart failure with reduced ejection fraction in China	24
Angiographic classification of total occlusion and its implication on balloon pulmonary angioplasty	24
Achieved dose and treatment discontinuation of candesartan in men and women with chronic heart failure: data from CHARM	24
Regional expert opinion: Management of heart failure with preserved ejection fraction in the Middle East, North Africa and Turkey	24
Left ventricular reverse remodelling as a promising strategy for resolving left ventricular thrombus	24
Issue Information	24
Letter to the editor regarding ‘Autopsy findings in cases of fatal COVID‐19 vaccine‐induced myocarditis’	24
SARS‐CoV‐2‐related Multisystem Inflammatory Syndrome in Adult complicated by myocarditis and cardiogenic shock	24
Performance of non‐invasive myocardial work to predict the first hospitalization for de novo heart failure with preserved ejection fraction	24
Transthyretin amyloid cardiomyopathy in aortic stenosis patients scheduled for transcatheter aortic valve implantation	24
Platelet count in heart failure patients undergoing left ventricular assist device	24
Effects of exercise modalities on physical function and quality of life in patients with heart failure: A systematic review and network meta‐analysis	23
Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017	23
Clinical characteristics of people with heart failure in Australian general practice: results from a retrospective cohort study	23
Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN‐HF study	23
Determinants of left ventricular function improvement for cardiac resynchronization therapy candidates	23
Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator	23
Outcomes after heart transplantation in patients with cardiac sarcoidosis	23
Effects of homoarginine supplementation on heart and skeletal muscle of rats with heart failure with preserved ejection fraction	23
Higher BNP/NT‐pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta‐analysis	23
Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross‐over trial	23
Identification of molecular signatures in epicardial adipose tissue in heart failure with preserved ejection fraction	22
Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial	22
Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode	22
Adaptive versus maladaptive right ventricular remodelling	22
Gender‐specific prevalence and trend of heart failure in China from 1990 to 2019	22
Changes over time in patient‐reported outcomes in patients with heart failure	22
A polygenic risk score of atrial fibrillation improves prediction of lifetime risk for heart failure	22
Takotsubo cardiomyopathy during armed conflict: A case series	22
Differences between cardiogenic shock related to acute decompensated heart failure and acute myocardial infarction	22
Sex‐based differences in referral of heart failure patients to outpatient clinics: a scoping review	22
Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single‐centre experience	22
Efficacy and safety of digital therapeutics‐based cardiac rehabilitation in heart failure patients: a systematic review	21
Human myocardial mitochondrial oxidative capacity is impaired in mild acute heart transplant rejection	21
Investigating the relationship between FRailty And Quality of LIfe in patients with heart faiLure and CKD (FRAIL study)	21
Considerations for drug trials in hypertrophic cardiomyopathy	21
The association between ivabradine and adverse cardiovascular events in acute decompensated HFrEF patients	21
Early diagnosis, disease stage and prognosis in wild‐type transthyretin amyloid cardiomyopathy: The DIAMOND study	21
Analysis of the usefulness and benefits of ultrafiltration in cardiorenal syndrome: A systematic review	21
A contemporary simple risk score for prediction of severe acute kidney injury after heart transplantation	21
Plasma volume status predicting clinical outcomes in patients undergoing transcatheter edge‐to‐edge mitral valve repair	20
Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure	20
Clinical application and immune infiltration landscape of stemness‐related genes in heart failure	20
Five‐year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort	20
A meta‐analysis of the relationship between glycaemic variability and the mortality of patients with heart failure	20
Cardiovascular vs. non‐cardiovascular deaths after heart failure hospitalization in young, older, and very old patients	20
Menopausal symptoms and risk of heart failure: a retrospective analysis from Taiwan National Health Insurance Database	20
Clinical performance and quality measures for heart failure management in China: the China‐Heart Failure registry study	20
Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real‐world study	20
Incidence, mortality, and predictors of acute kidney injury in patients with heart failure: a systematic review	20
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial	20
A qualitative exploration of participant and investigator perspectives from the TRED‐HF trial	19
Adequate immune response after SARS‐CoV‐2 infection and single dose vaccination despite rapid heart transplantation	19
E prostanoid receptor‐3 promotes oxidized low‐density lipoprotein‐induced human aortic smooth muscle cells inflammation	19
Association of iron deficiency with incident cardiovascular diseases and mortality in the general population	19
Effect of aggressive diuresis in acute heart failure with reduced and preserved ejection fraction	19
Prognostic impact of a history of cancer and atrial fibrillation in antithrombotic therapy for chronic heart failure	19
Response to Letter to the editor regarding ‘Discordance between estimated and measured changes in plasma volume among patients with acute heart failure’	19
Diagnostic and prognostic value of the left atrial myopathy evaluation in cardiac amyloidosis using echocardiography	19
The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta‐analysis	19

Impact of cardiac resynchronization therapy optimization inside a heart failure programme: a real‐world experience	19
Body mass index, frailty, and outcomes in heart failure with preserved ejection fraction	18
Letter regarding the article “Hypocapnia is an independent predictor of in‐hospital mortality in acute heart failure”	18
Novel electrocardiographic criteria may render possible the more accurate recognition of cardiac amyloidosis	18
Pre‐emptive treatment of heart failure exacerbations in patients managed with the HeartLogic™ algorithm	18
Impact of B‐lines‐guided intensive heart failure management on outcome of discharged heart failure patients with residual B‐lines	18
Corrigendum	18
Genotype is associated with left ventricular reverse remodelling and early events in recent‐onset dilated cardiomyopathy	18
Biomarkers in heart failure: Traditional and emerging indicators for prognosis	18
Tyrosine to threonine ratio was related to heart failure with reduced or mildly reduced ejection fraction	18
Cognitive transitions based on functional status in older adults with heart failure: a population‐based study	18
Predicted impact of atrial flow regulator on survival in heart failure with reduced and preserved ejection fraction	18
Narrative synthesis of the effectiveness and characteristics of heart failure disease self‐management support programmes	18
The efficacy and safety of sodium‐glucose cotransporter 2 inhibitors in patients aged over 80 years with heart failure	18
Temporal profiling of M‐TEER‐related complications	18
Estimated pulse wave velocity and risk of new‐onset heart failure	17
Effect of early intervention on short‐term prognosis of patients with myocardial injury induced by acute carbon monoxide poisoning	17
Fractional excretion of urea nitrogen can identify true worsening renal function in patients with heart failure	17
Variability in estimated glomerular filtration rate and patients' outcomes in a real‐world heart failure population	17
Sodium–glucose cotransporter 2 inhibitor‐induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction	17
Biomarker prognostication across Universal Definition of Heart Failure stages	17
Is ischaemic heart failure an autoimmune disease?	17
S2I2N0–3 score predicts short‐ and long‐term mortality and morbidity in HFrEF: a post‐hoc analysis of the GUIDE‐IT trial	17
Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE‐HF and PRESERVED‐HF	17
Susceptibility to infections and adaptive immunity in adults with heart failure	17
Prognostic impact of heart failure admission in survivors of acute myocardial infarction	17
Trametinib alters contractility of paediatric Noonan syndrome‐associated hypertrophic myocardial tissue slices	17
The characteristic large‐scale annual analysis by gender and age in heart failure patients: cohort for 10 years in Korea	17
Six‐months immunogenicity of BNT162b2 mRNA vaccine in heart transplanted and ventricle assist device‐supported patients	17
Low‐density lipoprotein cholesterol, erythrocyte, and platelet in heart failure with preserved ejection fraction	17
Interpretation of elevated baseline concentrations and serial changes of high‐sensitivity cardiac troponin T in confirmed muscular dystrophies	17
Presence of active myocarditis at the 6 month follow‐up appointment for a severe form of COVID‐19: a case report	17
Severe aortic insufficiency‐induced cardiogenic shock treated with left atrial VA‐ECMO and emergent valve‐in‐valve TAVR	17
Smartwatches in the assessment of heart failure patients in epidemiology and pathophysiology studies: A scoping review	17
Diabetes and treatment of chronic heart failure in a large real‐world heart failure population	17
Novel active fixation lead guided by electrical delay can improve response to cardiac resynchronization therapy in heart failure	17
Relationship between haemodynamic indicators and haemogram in patients with heart failure	16
Cardiac resynchronization therapy defibrillators in patients with permanent atrial fibrillation	16
IgM‐enriched immunoglobulin as adjuvant therapy for heart transplant after infection of left ventricular assist devices	16
Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: correspondence	16
A nationwide study of temporal trends of cause‐specific hospital readmissions in patients with heart failure	16
Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure	16
Comprehensive exploration of unexplained dyspnoea in subjects with normal ejection fraction and low natriuretic peptides	16
Serum a‐1 antitrypsin as a novel biomarker in chronic heart failure	16
Correction to: “Obesity and contraceptive use: impact on cardiovascular risk”	16
Systematic review of sodium‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events	16
Sodium‐glucose transporter 2 inhibitors may improve the prognosis of acute heart failure by correcting hypocapnia	16
The HFA‐PEFF score identifies ‘early‐HFpEF’ phenogroups associated with distinct biomarker profiles	16
Impact of the COVID‐19 pandemic on management and outcomes of patients with acute heart failure	16
The association between cardiac involvement and long‐term clinical outcomes in patients with Duchenne muscular dystrophy	16
Successful percutaneous treatment of late outflow graft failure of the left ventricular assist device: a long‐term follow‐up	16
Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis	16
Effects of bariatric surgery on cardiovascular‐related acute care use in patients with hypertrophic cardiomyopathy	16
Newly diagnosed atrial fibrillation and hospital utilization in heart failure: a nationwide cohort study	16
Safety and efficacy of MitraClip in acutely ill (NYHA Class IV) patients with mitral regurgitation: Results from the global EXPAND study	16
Issue Information	16
Letter to the editor regarding ‘Discordance between estimated and measured changes in plasma volume among patients with acute heart failure’	16
Coronary angiography in patients with acute heart failure: from the KCHF registry	16
Prognostic implications of functional tricuspid regurgitation in asymptomatic degenerative mitral regurgitation	16
Issue Information	16
Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure	15
Issue Information	15
Parvovirus B19 DNA detectable in hearts of patients with dilated cardiomyopathy, but absent or inactive in blood	15
Applying the ESC 2016, H2FPEF, and HFA‐PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the general population	15
Non‐dilated left ventricular cardiomyopathy vs. dilated cardiomyopathy: clinical background and outcomes	15
Frailty alone and interactively with obesity predicts heart failure: Kuopio Ischaemic Heart Disease Risk Factor Study	15
Initial experience with transcatheter tricuspid valve repair in patients with cardiac amyloidosis	15
Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild‐type transthyretin amyloid cardiomyopathy	15
Clinical profile and 90 day outcomes of 10 851 heart failure patients across India: National Heart Failure Registry	15
Integrin beta‐like 1 is regulated by DNA methylation and increased in heart failure patients	15
Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure	15
Characterization of critically ill patients with septic shock and sepsis‐associated cardiomyopathy using cardiovascular MRI	15
Advanced heart failure: guideline‐directed medical therapy, diuretics, inotropes, and palliative care	15
Relationship of atrial fibrillation and N terminal pro brain natriuretic peptide in heart failure patients	15
Construction of a web‐based dynamic nomogram for predicting the prognosis in acute heart failure	15
Short‐term outcomes after sodium‐glucose cotransporter‐2 inhibitor initiation in a cohort of heart failure patients	15
Mavacamten in real‐life practice: Initial experience at a hypertrophic cardiomyopathy centre	15
Diuretic dose is a strong prognostic factor in ambulatory patients awaiting heart transplantation	15
Eniluracil blocks AREG signalling‐induced pro‐inflammatory fibroblasts of melanoma in heart failure	15
Utilizing longitudinal data in assessing all‐cause mortality in patients hospitalized with heart failure	15
Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?	15
Paediatric heart transplantation during the COVID‐19 pandemic in Iran: single‐centre experience	15
Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i	15
Cardiac arrest caused by coronary occlusion during transcatheter aortic valve implantation: a unique cause	15
Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters	15
Circulating growth differentiation factor‐15 as a novel biomarker in heart transplant	15
Pressure–strain loops unveil haemodynamics behind mechanical circulatory support systems	14
Decoding cardiogenic shock: assessing shock index and its variants as prognostic indicators for in‐hospital mortality	14
Sodium‐glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review	14
Prognostic value of high‐sensitivity cardiac troponin I in patients with non‐ischaemic heart failure: insights from China	14
Safety and efficacy of up to 60 h of iv istaroxime in pre‐cardiogenic shock patients: Design of the SEISMiC trial	14
HFA of the ESC position paper on the management of LVAD‐supported patients for the non‐LVAD specialist healthcare provider Part 3: at the hospital and discharge	14
Vericiguat improves cardiac remodelling and function in rats with doxorubicin‐induced cardiomyopathy	14
Association between trimethylamine N‐oxide and prognosis of patients with acute myocardial infarction and heart failure	14
	14